PFE

SEC source: 0001225208-25-002612 · doc4.xml · nonDerivative · entry 1

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,972

F1 · shares: The reported transaction constitutes the earn-out of performance share awards (including dividend equivalents thereon).

SEC source: 0001225208-25-002613 · doc4.xml · nonDerivative · entry 1

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,994

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-25-002702 · doc4a.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,647

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-25-002701 · doc4a.xml · nonDerivative · entry 1

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,882

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-25-002397 · doc4.xml · nonDerivative · entry 4

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,285

F6 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002412 · doc4.xml · nonDerivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,024

F6 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002397 · doc4.xml · derivative · entry 6

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,741 shares

Expires 2025-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002397 · doc4.xml · nonDerivative · entry 3

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,947

F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002397 · doc4.xml · nonDerivative · entry 2

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,745

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002397 · doc4.xml · nonDerivative · entry 1

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,085

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002400 · doc4.xml · derivative · entry 5

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,714 shares

Expires 2025-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002400 · doc4.xml · nonDerivative · entry 3

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,188

F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002400 · doc4.xml · nonDerivative · entry 2

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,531

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002400 · doc4.xml · nonDerivative · entry 1

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,099

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002399 · doc4.xml · derivative · entry 5

SUSMAN SALLY · CIK 0001263544 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 63,573 shares

Expires 2025-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002399 · doc4.xml · nonDerivative · entry 3

SUSMAN SALLY · CIK 0001263544 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,684

F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002399 · doc4.xml · nonDerivative · entry 2

SUSMAN SALLY · CIK 0001263544 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,399

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002399 · doc4.xml · nonDerivative · entry 1

SUSMAN SALLY · CIK 0001263544 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,184

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002401 · doc4.xml · derivative · entry 5

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 85,824 shares

Expires 2025-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002401 · doc4.xml · nonDerivative · entry 3

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,876

F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002401 · doc4.xml · nonDerivative · entry 2

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 229,441

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002401 · doc4.xml · nonDerivative · entry 1

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,775

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002402 · doc4.xml · derivative · entry 5

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 238,399 shares

Expires 2025-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002402 · doc4.xml · nonDerivative · entry 3

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 348,921

F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002402 · doc4.xml · nonDerivative · entry 2

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 561,601

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002402 · doc4.xml · nonDerivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 570,436

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002412 · doc4.xml · derivative · entry 5

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,741 shares

Expires 2025-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002412 · doc4.xml · nonDerivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,414

F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002412 · doc4.xml · nonDerivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,212

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002412 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,602

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-002413 · doc4.xml · derivative · entry 4

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,125 shares

Expires 2025-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002413 · doc4.xml · nonDerivative · entry 3

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,214

F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002413 · doc4.xml · nonDerivative · entry 2

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,139

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002413 · doc4.xml · nonDerivative · entry 1

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,636

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-001778 · doc4.xml · nonDerivative · entry 1

BLAYLOCK RONALD E · CIK 0001214686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,707

SEC source: 0001225208-25-001805 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 702,791

Underlying: Common Stock · 625 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-25-001142 · doc4.xml · nonDerivative · entry 1

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,344

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-25-000644 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 690,650

Underlying: Common Stock · 75 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-25-000085 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 690,585

Underlying: Common Stock · 20 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-25-000119 · doc4.xml · derivative · entry 1

Echevarria Joseph · CIK 0001633137 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,639.287

Underlying: Common Stock · 1,743.309 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

SEC source: 0001225208-25-000120 · doc4.xml · derivative · entry 1

NARAYEN SHANTANU · CIK 0001224154 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,711.283

Underlying: Common Stock · 1,884.659 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

SEC source: 0001225208-25-000121 · doc4.xml · derivative · entry 1

Quincey James · CIK 0001561264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,028.61

Underlying: Common Stock · 1,460.611 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

SEC source: 0001225208-25-000132 · doc4.xml · derivative · entry 1

JOHNSON RADY A · CIK 0001594762 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,379

Underlying: Common Stock · 7 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-25-000134 · doc4.xml · derivative · entry 1

SMITH JAMES C · CIK 0001611777 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,543.661

Underlying: Common Stock · 1,696.193 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

SEC source: 0001225208-25-000133 · doc4.xml · derivative · entry 1

Taraporevala Cyrus · CIK 0001454920 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,083.695

Underlying: Common Stock · 1,413.494 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

SEC source: 0001225208-24-010859 · doc4.xml · derivative · entry 1

JOHNSON RADY A · CIK 0001594762 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,373

Underlying: Common Stock · 7 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-010893 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 690,626

Underlying: Common Stock · 21 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-010307 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 690,388

Underlying: Common Stock · 20 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-010308 · doc4.xml · derivative · entry 1

JOHNSON RADY A · CIK 0001594762 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,363

Underlying: Common Stock · 7 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-010029 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 691,116

Underlying: Common Stock · 21 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.